Home  >>  BioRN Annual Conference  >>  Speakers

Neil J. Gallagher

Vice President and Head of Global Oncology Development

Neil Gallagher joined AbbVie in 2017 as Vice President and Head of Global Oncology Development. A gynecological oncologist by training with more than fifteen years’ experience focusing on oncology drug development across all phases of development at several companies including: AstraZeneca, Astex Therapeutics, Novartis and Amgen. In his current role, he oversees the Hematology and Oncology Therapeutic Areas, Co-Chairs the Oncology TASC and is a member of the Development Leadership Team.

Thomas Hoeger

Chief Executive Officer


Thomas Hoeger has been Chief Executive Officer of Apogenix since November 2005. Previously, he worked as a biotech analyst for DZ Bank in Frankfurt, Germany, for five years. From 1997 to 2000, he headed the 'Central Nervous System' research at BASF AG and Knoll AG. During the previous six years, he held various research and management positions at BASF AG.

joern peter halle compact

Joern-Peter Halle

Senior Vice President, Head Translational Innovation Platform Immuno-Oncology and Head External Innovation Merck KGaA, Darmstadt, Germany
Peter Halle is leading the Translational Innovation Platform Immuno-Oncology with global responsibility for the research, discovery, and translational aspects of Merck KGaA’s IO portfolio. As the global head for External Innovation he oversees the search & evaluation of external opportunities in all therapeutic areas ranging from academic collaborations to clinical assets. He is also a member of the investment committee of Merck Venture, Merck KGaA’s corporate VC. Prior to joining Merck KGaA, he co-founded a biotech company focusing on R&D in dermatology where he was responsible for IP, bioinformatics, and technology development and served as a Chief Business Officer.

Dirk Jaeger

Director Medical Oncology National Center for Tumor Diseases University Medical Center Heidelberg
Dirk Jaeger began his scientific career at Cancer Research Institute, New York at the Department of Pathology, Cornell Medical Center, New York, and the Ludwig Institute, New York Branch (1998-2000). Subsequently, he joined the Department of Hematology/Oncology, Krankenhaus Nordwest, Frankfurt as head of the Research Group `Tumor antigen identification and characterization´(2001-2003). He moved on to the University Hospital Zurich, as PI of the Laboratory for Tumor Immunology at the Oncology Department (2003-2005). Since 2005 until today he works at the NCT in Heidelberg.

Rienk Offringa

Head of Molecular Oncology of Gastrointestinal Tumors and DKFZ-Bayer Immunotherapeutics Laboratory, DKFZ
Rienk Offringa is currently running two labs, one focusing on pancreatic cancer and cancer immunotherapy, and a second dedicated to the development of cancer immunotherapy drugs, co-funded by DKFZ and Bayer Healthcare. After 4 years in Industry (in 2011), he moved back to academia and back to Europe, by accepting a full professorship at University Hospital Heidelberg and DKFZ. He is currently running two labs, one focusing on pancreatic cancer and cancer immunotherapy, and a second dedicated to the development of cancer immunotherapy drugs, co-funded by DKFZ and Bayer Healthcare.

Julia Schaft

Project Manager
BioRN Cluster

Julia Schaft joined BioRN in 2016 as a project manager for international R&D and translational initiatives in the life sciences sector. In addition she is taking on BioRN strategic business development and partnering responsibilities. Previously, she performed scientific research and covered leadership responsibilities in scientific project management at Genea Ltd in Sydney Australia. She completed her PhD in molecular and developmental biology at the University of Giessen and the European Molecular Biology Laboratory in Heidelberg (Germany) in 2002.

Gerty Schreibelt

Senior Scientist, Tumor Immunology Radboud University
After obtaining her PhD, Gerty Schreibelt joined the department of Tumor Immunology in Nijmegen, where she studies the use of dendritic cells as anti-cancer vaccines. Her research primarily focuses on human natural circulating DC subsets, to understand the functional properties of these dendritic cells and to establish their value for clinical vaccination of cancer. She is highly involved in clinical trials with dendritic cell vaccination of cancer, to translate findings from preclinical studies into new immunological approaches for treatment of cancer patients.

Martin Treder

Chief Scientific Officer, Affimed

Martin Treder joined Affimed’s Management Team in 2015 as Chief Scientific Officer. Dr. Treder has more than 15 years of professional experience in the field of biotherapeutics research and development and broad experience in immuno-oncology discovery and pre-clinical development of antibodies. Before joining Affimed, he co-founded CT Atlantic AG, a Swiss biotechnology company focused on the identification and development of human-derived monoclonal antibodies for the treatment of cancer.